Witte Owen N.'s Form 4 filing
Allogene Therapeutics, Inc. (ALLO) · filed Aug 15, 2022
- Accession no.
- 0001737287-22-000069
- Filed
- Aug 15, 2022
- Trade date
- Aug 11-12, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $251.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Witte Owen N.CIK 0001700969 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 11, 2022 | Common Stock | SSaleDisposed | −10,000 | $16.50 | −$165,000 | 223,271 | Direct | Duplicate filing |
| Aug 12, 2022 | Common Stock | SSaleDisposed | −5,000 | $17.25 | −$86,250 | 218,271 | Direct | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.